Regulation of Human p53 Activity and Cell Localization by Alternative Splicing

REFERENCES

• Balint, E., and Vousden K.. 2001. Activation and activities of the p53 tumor suppressor protein. Br. J. Cancer 85:1813–1823.
   PubMed Web of Science ®Google Scholar
• Boyd, S., Tsai K., and Jacks T. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563–568.
   PubMed Web of Science ®Google Scholar
• Courtois, S., Verhaegh G., North S., Luciani M. G., Lassus P., Hibner U., Oren M., and Hainaut P.. 2002. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counters growth suppression by wild-type p53. Oncogene 21:6722–6728.
   PubMed Web of Science ®Google Scholar
• Donehower, L. 1996. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7:269–278.
   PubMedGoogle Scholar
• Freedman, D., and Levine A.. 1998. Nuclear export is required for degradation of endogenous p53 by Mdm2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288–7293.
   PubMed Web of Science ®Google Scholar
• Geyer, R., Yu Z., and Maki C.. 2000. The MDM2 Ring-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:569–573.
   PubMed Web of Science ®Google Scholar
• Hahn, W., and Weinberg R.. 2002. Rules for making human tumor cells. N. Engl. J. Med. 347:1593–1603.
   PubMed Web of Science ®Google Scholar
• Jimenez, G., Khan S., Stommel J., and Wahl G.. 1999. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18:7656–7665.
   PubMedGoogle Scholar
• Kaelin, W. 1999. The p53 gene family. Oncogene 18:7701–7705.
   PubMedGoogle Scholar
• Lamb, P., and Crawford L.. 1986. Characterization of the human p53 gene. Mol. Cell. Biol. 5:1379–1385.
   Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Li, M., Brooks, C., Wu-Baer, F., Chen D., Baer R., and Gu W.. 2003. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302:1972–1975.
   PubMed Web of Science ®Google Scholar
• Li, M., Brooks C., Kon N., and Gu W.. 2004. A dynamic role for HAUSP in the p53-Mdm2 pathway. Mol. Cell 13:879–886.
   PubMed Web of Science ®Google Scholar
• Maier, B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., A., Sutherland, Thorner M., and Scrable H.. 2003. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18:306–319.
   Google Scholar
• Malkin, D., Li F., Strong L., Fraumini J., Nelson C., Kim D., Kassel J., Gryka M., Bischoff F., Tainsky M., and Friend S.. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias. Science 250:1233–1238.
   PubMed Web of Science ®Google Scholar
• Matlashewski, G., Lamb P., Pim D., Peacock J., Crawford L., and Benchimol S.. 1984. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 3:3257–3262.
   PubMed Web of Science ®Google Scholar
• Matlashewski, G., Pim D., Banks L., and Crawford L.. 1987. Alternative splicing of human p53 transcripts. Oncogene Res. 1:79–88.
   Google Scholar
• Matlashewski, G. J., Tuck S., Pim D., Lamb P., Schneider J., and Crawford L. V.. 1987. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 7:961–963.
   PubMed Web of Science ®Google Scholar
• Melino, G., DeLaurenzi V., and Vousden K.. 2002. p73: Friend or foe in tumorigenesis. Nat. Rev. Cancer 2:1–11.
   Google Scholar
• Mowat, M., Cheng A., Kimura A., Bernstein A., and Benchimol S.. 1985. Rearrangement of the cellular p53 gene in erythroleukemia cells transformed by Friend virus. Nature 314:633–636.
   PubMed Web of Science ®Google Scholar
• Rovinski, B., Munroe D., Peacock J., Mowat M., Berstein A., and Benchimol S.. 1987. Delection of 5′-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol. Cell. Biol. 7:847–853.
   PubMed Web of Science ®Google Scholar
• Shaulsky, G., Goldfinger N., Ben-Ze'ev A., and Rotter V.. 1990. Nuclear accumulation of p53 is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:6565–6577.
   PubMed Web of Science ®Google Scholar
• Stommel, J., Marchenko N., Jimenez G., Moll U., Hope T., and Wahl G.. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660–1672.
   PubMed Web of Science ®Google Scholar
• Sturzbecher, H. W., Brain R., Addison C., Rudge K., Remm M., Grimaldi M., Keenan E., and Jenkins J. R.. 1992. C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513–1523.
   PubMedGoogle Scholar
• Thomas, M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G.. 1999. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19:1092–1101.
   PubMed Web of Science ®Google Scholar
• Yin, Y., Luciana M.-G., and Fahraeus R.. 2002. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 4:462–467.
   PubMed Web of Science ®Google Scholar
• Zaika, A. I., Slade N., Erster S. H., Sansome C., Joseph T. W., Pearl M., Chalas E., and Moll U. M.. 2002. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196:765–780.
   PubMed Web of Science ®Google Scholar